Jade Biosciences, Inc. (JBIO)

Jade Biosciences, Inc. is a clinical-stage biotechnology company developing antibody therapies for autoimmune and inflammatory diseases. It became publicly traded on the Nasdaq after merging with Aerovate Therapeutics in 2025.

The company's lead program is an antibody that targets APRIL, a protein involved in the production of a form of immunoglobulin A that drives IgA nephropathy, a chronic kidney disease. Jade is also developing additional antibody candidates for other immune-mediated conditions, designed with extended half-lives to allow less frequent dosing.

As a clinical-stage company, Jade Biosciences has no approved products, and its work centers on advancing its candidates through clinical trials.